Reshma has dedicated her career to improving the lives of patients, including the last 15+ years through the development of new medicines. She joined Vertex in 2017 and, in collaboration with the executive committee, board of directors and everyone at Vertex, she leads and executes the company’s strategy and ambitious mission of transforming the lives of people with serious diseases. Prior to taking on her role as CEO and President, she was the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs.
She earned her medical degree, with honors, from the seven-year medicine program at the Boston University School of Medicine and completed the General Management Program at Harvard Business School. She completed her internship and residency in internal medicine at the Massachusetts General Hospital (MGH) and her fellowship in nephrology through the MGH and Brigham and Women’s Hospital combined program.
Reshma is passionate about developing and supporting the next generation of scientists and giving back to her community — serving as a member of the board of directors of the Biomedical Science Careers Program, an organization dedicated to supporting underrepresented students to pursue a career in STEM. She’s also a member of the Boston University School of Medicine Dean’s Advisory Board, the MGH Board of Trustees, and the Ginkgo Bioworks board of directors. She is a Fellow of the American Society of Nephrology and was on the inaugural board of directors of the Kidney Health Initiative.
She is the recipient of the Harvard Medical School Excellence in Teaching Award. In 2019, Reshma received the TiE Boston Healthcare Leadership Award and was named one of Boston Business Journal’s Power 50. In 2020, Business Insider named her one of 10 people transforming health care, and she was included on the PharmaVOICE 100 list of the most inspiring and influential leaders in the life sciences and Boston Business Journal’s list of Women Who Mean Business. In 2021, Dr. Kewalramani received the Golden Door Award from the International Institute of New England and was named a New Englander of the Year by the New England Council. Under her leadership as CEO, Vertex was ranked #2 on The Commonwealth Institute’s Top Women-Led Businesses in Massachusetts in 2021.
How old is Reshma Kewalramani FASN?
Dr. FASN is currently 51 years old. There are 6 older executives and no younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals is Dr. Jeffrey Marc Leiden M.D., Ph.D., Executive Chairman, who is 68 years old. Learn More on Reshma Kewalramani FASN's age.
How do I contact Reshma Kewalramani FASN?
Has Reshma Kewalramani FASN been buying or selling shares of Vertex Pharmaceuticals?
Who are Vertex Pharmaceuticals' active insiders?
Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?
During the last year, insiders at the pharmaceutical company sold shares 24 times. They sold a total of 96,063 shares worth more than $43,158,852.08. The most recent insider tranaction occured on August, 30th when Chairman Jeffrey M Leiden sold 3,784 shares worth more than $1,888,216.00. Insiders at Vertex Pharmaceuticals own 0.2% of the company.
Learn More about insider trades at Vertex Pharmaceuticals. Information on this page was last updated on 8/30/2024.
